Comerica Bank Has $46.70 Million Holdings in Amgen Inc. $AMGN

Comerica Bank decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 6.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 165,469 shares of the medical research company’s stock after selling 12,190 shares during the period. Comerica Bank’s holdings in Amgen were worth $46,695,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in AMGN. Texas Capital Bank Wealth Management Services Inc increased its holdings in shares of Amgen by 24.3% in the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 3,202 shares of the medical research company’s stock valued at $904,000 after purchasing an additional 626 shares during the last quarter. Wealth Advisors of Tampa Bay LLC lifted its stake in shares of Amgen by 11.7% during the 3rd quarter. Wealth Advisors of Tampa Bay LLC now owns 2,292 shares of the medical research company’s stock worth $647,000 after buying an additional 240 shares during the last quarter. Mcintyre Freedman & Flynn Investment Advisers Inc. lifted its stake in shares of Amgen by 86.9% during the 3rd quarter. Mcintyre Freedman & Flynn Investment Advisers Inc. now owns 1,574 shares of the medical research company’s stock worth $444,000 after buying an additional 732 shares during the last quarter. Regal Investment Advisors LLC boosted its holdings in shares of Amgen by 3.9% during the 3rd quarter. Regal Investment Advisors LLC now owns 4,779 shares of the medical research company’s stock worth $1,349,000 after buying an additional 179 shares during the period. Finally, Cadence Bank grew its stake in Amgen by 2.7% in the 3rd quarter. Cadence Bank now owns 5,506 shares of the medical research company’s stock valued at $1,554,000 after buying an additional 145 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $366.21 on Friday. The company’s 50 day moving average price is $357.73 and its two-hundred day moving average price is $325.17. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market cap of $197.41 billion, a PE ratio of 25.74, a PEG ratio of 3.65 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period last year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is 70.84%.

Analysts Set New Price Targets

Several research firms have weighed in on AMGN. Deutsche Bank Aktiengesellschaft increased their price target on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a report on Thursday, February 5th. Freedom Capital cut Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Argus upped their target price on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Barclays assumed coverage on Amgen in a research note on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price on the stock. Finally, Oppenheimer set a $400.00 price target on Amgen and gave the company an “outperform” rating in a research note on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $354.00.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen (NASDAQ:AMGN) Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis – Amgen, Inc.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.